Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

von Tarantelli, Chiara, Lupia, Antonio, Stathis, Anastasios, Bertoni, Francesco
Veröffentlicht in Int J Mol Sci (2020)

An Unusual Case of Plasmablastic Lymphoma Presenting as Paravertebral Mass Evaluated by (18) F-FDG PET/CT

von Treglia, Giorgio, Paone, Gaetano, Stathis, Anastasios, Ceriani, Luca, Giovanella, Luca
Veröffentlicht 2013

Genetic alterations in systemic nodal and extranodal non‐cutaneous lymphomas derived from mature T cells and natural killer cells

von Boi, Michela, Stathis, Anastasios, Zucca, Emanuele, Inghirami, Giorgio, Bertoni, Francesco
Veröffentlicht in Cancer Sci (2012)

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase

von Noseda, Roberta, Bonaldo, Giulia, Motola, Domenico, Stathis, Anastasios, Ceschi, Alessandro
Veröffentlicht in Cancers (Basel) (2021)

Do oncologists prefer subspecialty radiology reports? A quality care study

von Rizzo, Stefania, Del Grande, Maria, Espeli, Vittoria, Stathis, Anastasios, Nicolino, Gabriele Maria, Del Grande, Filippo
Veröffentlicht in Insights Imaging (2021)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-esca...

von Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Veröffentlicht in Invest New Drugs (2018)

Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response

von Mensah, Afua Adjeiwaa, Kwee, Ivo, Gaudio, Eugenio, Rinaldi, Andrea, Ponzoni, Maurilio, Cascione, Luciano, Fossati, Gianluca, Stathis, Anastasios, Zucca, Emanuele, Caprini, Gianluca, Bertoni, Francesco
Veröffentlicht in Oncotarget (2014)

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

von Tarantelli, Chiara, Zhang, Lu, Curti, Elisabetta, Gaudio, Eugenio, Spriano, Filippo, Priebe, Valdemar, Cascione, Luciano, Arribas, Alberto J., Zucca, Emanuele, Rossi, Davide, Stathis, Anastasios, Bertoni, Francesco
Veröffentlicht in Haematologica (2019)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

von Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Veröffentlicht in Oncotarget (2016)

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

von Stathis, Anastasios, Zucca, Emanuele, Bekradda, Mohamed, Gomez-Roca, Carlos, Delord, Jean-Pierre, de La Motte Rouge, Thibault, Uro-Coste, Emmanuelle, de Braud, Filippo, Pelosi, Giuseppe, French, Christopher A.
Veröffentlicht in Cancer Discov (2016)

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

von Tarantelli, Chiara, Gaudio, Eugenio, Hillmann, Petra, Spriano, Filippo, Sartori, Giulio, Aresu, Luca, Cascione, Luciano, Rageot, Denise, Kwee, Ivo, Beaufils, Florent, Zucca, Emanuele, Stathis, Anastasios, Wymann, Matthias P., Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco
Veröffentlicht in Cancers (Basel) (2019)

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

von Joerger, Markus, Stathis, Anastasios, Metaxas, Yannis, Hess, Dagmar, Mantiero, Mara, Mark, Michael, Volden, Matthias, Kaindl, Thomas, Engelhardt, Marc, Larger, Patrice, Lane, Heidi, Hafner, Peter, Levy, Nicole, Stuedeli, Silvia, Sessa, Cristiana, von Moos, Roger
Veröffentlicht in Invest New Drugs (2019)

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

von Mensah, Afua Adjeiwaa, Spriano, Filippo, Sartori, Giulio, Priebe, Valdemar, Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Civanelli, Elisa, Aresu, Luca, Rinaldi, Andrea, Damia, Giovanna, Lovati, Emanuela, Zucca, Emanuele, Stathis, Anastasios, Pietra, Claudio, Bertoni, Francesco
Veröffentlicht in Blood Adv (2021)

Pembrolizumab in relapsed or refractory Richter syndrome

von Armand, Philippe, Murawski, Niels, Molin, Daniel, Zain, Jasmine, Eichhorst, Barbara, Gulbas, Zafer, Hawkes, Eliza A., Pagel, John M., Phillips, Tycel, Ribrag, Vincent, Svoboda, Jakub, Stathis, Anastasios, Chatterjee, Arkendu, Orlowski, Robert, Marinello, Patricia, Christian, Beth
Veröffentlicht in Br J Haematol (2020)

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

von Ceriani, Luca, Gritti, Giuseppe, Cascione, Luciano, Pirosa, Maria Cristina, Polino, Angela, Ruberto, Teresa, Stathis, Anastasios, Bruno, Andrea, Moccia, Alden A., Giovanella, Luca, Hayoz, Stefanie, Schär, Sämi, Dirnhofer, Stefan, Rambaldi, Alessandro, Martinelli, Giovanni, Mamot, Christoph, Zucca, Emanuele
Veröffentlicht in Blood Adv (2020)

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

von Mensah, Afua A., Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Bomben, Riccardo, Bernasconi, Elena, Zito, Domenico, Lampis, Andrea, Hahne, Jens C., Rinaldi, Andrea, Stathis, Anastasios, Zucca, Emanuele, Kwee, Ivo, Gattei, Valter, Valeri, Nicola, Riveiro, Maria E, Bertoni, Francesco
Veröffentlicht in Haematologica (2018)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

von Tarantelli, Chiara, Bernasconi, Elena, Gaudio, Eugenio, Cascione, Luciano, Restelli, Valentina, Arribas, Alberto Jesus, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua Adjeiwaa, Kwee, Ivo, Ponzoni, Maurilio, Zucca, Emanuele, Carrassa, Laura, Riveiro, Maria E, Rezai, Keyvan, Stathis, Anastasios, Cvitkovic, Esteban, Bertoni, Francesco
Veröffentlicht in ESMO Open (2018)

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

von Spriano, Filippo, Gaudio, Eugenio, Cascione, Luciano, Tarantelli, Chiara, Melle, Federica, Motta, Giovanna, Priebe, Valdemar, Rinaldi, Andrea, Golino, Gaetanina, Mensah, Afua Adjeiwaa, Aresu, Luca, Zucca, Emanuele, Pileri, Stefano, Witcher, Michael, Brown, Bill, Wahlestedt, Claes, Giles, Francis, Stathis, Anastasios, Bertoni, Francesco
Veröffentlicht in Blood Adv (2020)

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

von Hicks, Stuart W., Tarantelli, Chiara, Wilhem, Alan, Gaudio, Eugenio, Li, Min, Arribas, Alberto J., Spriano, Filippo, Bordone, Roberta, Cascione, Luciano, Lai, Katharine C., Qiu, Qifeng, Taborelli, Monica, Rossi, Davide, Stussi, Georg, Zucca, Emanuele, Stathis, Anastasios, Sloss, Callum M., Bertoni, Francesco
Veröffentlicht in Haematologica (2019)

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas

von Stathis, Anastasios, Hotte, Sebastien J., Chen, Eric X., Hirte, Holger W., Oza, Amit M., Moretto, Patricia, Webster, Sheila, Laughlin, Anne, Stayner, Lee-Anne, McGill, Shauna, Wang, Lisa, Zhang, Wen-jiang, Espinoza-Delgado, Igor, Holleran, Julianne L., Egorin, Merrill J., Siu, Lillian L.
Veröffentlicht 2009